Two recent studies—one in humans by Levine et al. in 2004 and one in mice by Venkatesha et al. in 2006—have shown an important role for placental-derived soluble antiangiogenic factors as mediators of the pathologies associated with preeclampsia. These findings may have profound implications for the diagnosis, treatment and prevention of this devastating condition.
This is a preview of subscription content, log in via an institution to check access.
References
Sibai, B. et al. Lancet 365, 785–799 (2005).
Khaliq, A. et al. Lab. Invest. 79, 151–170 (1999).
Park, J.E. et al. J. Biol. Chem. 269, 25646–25654 (1994).
Maynard, S.E. et al. J. Clin. Invest. 111, 649–658 (2003).
Levine, R.J. et al. N. Engl. J. Med. 350, 672–683 (2004).
Venkatesha, S. et al. Nat. Med. 12, 642–649 (2006).
Levine, R.J. et al. N. Engl. J. Med. 355, 992–1005 (2006).
Kanasaki, K. et al. Nature 453, 1117–1121 (2008).
Davoodpour, P. & Landström, M. J. Biol. Chem. 280, 14773–14779 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dechend, R., Luft, F. Angiogenesis factors and preeclampsia. Nat Med 14, 1187–1188 (2008). https://doi.org/10.1038/nm1108-1187
Issue Date:
DOI: https://doi.org/10.1038/nm1108-1187
- Springer Nature America, Inc.
This article is cited by
-
A blood-based miRNA signature for early non-invasive diagnosis of preeclampsia
BMC Medicine (2022)
-
Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie
Der Urologe (2016)
-
Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy
BMC Research Notes (2015)
-
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
British Journal of Cancer (2015)